TA183 Cervical cancer (recurrent) - topotecan: review decision - December 2012
Review of NICE Technology Appraisal Guidance No. 183; Topotecan for the treatment of recurrent carcinoma of the cervix
The Institute was proposing that TA183 should be transferred to the static guidance list.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.
TA183 will therefore be moved to the static guidance list, however if NICE is notified of a significant change to the evidence base at any stage within the next 5 years then this could trigger a review proposal.
This page was last updated: 27 November 2012